Výsledky vyhledávání

Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)

Autor: J Pikiel, M de Silvio, Elżbieta Starosławska, Etienne Brain, P Potemski, FJ Sapunar, Boguslawa Karaszewska, Christos Papadimitriou, Wolfgang Janni, C Caglevic, K Briggs, Christoph Salat, T Sarosiek

Publikováno v: Cancer Research. 72:P5-18

Background: Lapatinib (L), a dual kinase inhibitor of epidermal growth factor receptor and ErbB2, is effective in the treatment of ErbB2+ MBC in combination with capecitabine (C) following progression after trastuzumab, anthracyclines, and taxanes. V

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7810f0b64d6911b019e631baa794a7e3
https://doi.org/10.1158/0008-5472.sabcs12-p5-18-21

Zobrazit plný text záznamu

OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer

Autor: Boguslawa Karaszewska, RA Herve, FJ Sapunar, Gallego J Alavarez, K Briggs, LS Williams, Christos Papadimitriou, T Sarosiek, K Schwedler, M Caruso, J Pikiel, Wolfgang Janni, Lau

Publikováno v: Cancer Research. 71:OT1-02

Background: Lapatinib, a dual kinase inhibitor of epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER2/ErbB2), is approved for the treatment of HER2−overexpressing (HER2+) metastatic breast cancer (MBC) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27b1374491c059c367cca27c93e80542
https://doi.org/10.1158/0008-5472.sabcs11-ot1-02-09

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání